Despite the data that major depressive disorder (MDD) is common during pregnancy and that pregnant women prefer nonmedication treatment options, there is a paucity of research examining alternative treatments for this special population. We present the results of an open label pilot study examining treatment with transcranial magnetic stimulation (TMS) in pregnant women with MDD.
Methods:
Ten women with MDD in the second or third trimester of pregnancy were treated with 20 sessions of 1-Hz TMS at 100% of motor threshold (MT) to the right dorsolateral prefrontal cortex. The total study dose was 6000 pulses. Antenatal monitoring was performed during treatment sessions 1, 10, and 20.
Results:
Seven of ten (70%) subjects responded (decrease ≥50% in Hamilton Depression Rating Scale [HDRS-17] scores). No adverse pregnancy or fetal outcomes were observed. All infants were admitted to the well baby nursery and were discharged with the mother. Mild headache was the only common adverse event and was reported by 4 of 10 (40%) subjects.
Conclusions:
TMS appears to be a promising treatment option for pregnant women who do not wish to take antidepressant medications.
Get full access to this article
View all access options for this article.
References
1.
JosefssonA, BergG, NordinC, SydsjoG. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand, 2001; 80:251–255.
2.
YonkersKA, WisnerKL, StewartDEet. The management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol, 2009; 114:703–713.
3.
FlynnHA, ChermackST. Prenatal alcohol use: The role of lifetime problems with alcohol, drugs, depression, and violence. J Stud Alcohol Drugs, 2008; 69:500–509.
4.
HannaEZ, FadenVB, DufourMC. The motivational correlates of drinking, smoking, and illicit drug use during pregnancy. J Subst Abuse, 1994; 6:155–167.
5.
MarcusSM, FlynnHA, BlowFC, BarryKL. Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health, 2003; 12:373–380.
6.
WisnerKL, ZarinDA, HolmboeESet al.Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry, 2000; 157:1933–1940.
7.
SuriR, AltshulerL, HellemannG, BurtVK, AquinoA, MintzJ. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry, 2007; 164:1206–1213.
8.
KurkiT, HiilesmaaV, RaitasaloR, MattilaH, YlikorkalaO. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol, 2000; 95:487–490.
9.
FieldT, DiegoM, Hernandez-ReifMet al.Depressed pregnant black women have a greater incidence of prematurity and low birthweight outcomes. Infant Behav Dev, 2009; 32:10–16.
10.
FieldT, DiegoM, Hernandez-ReifMet al.Comorbid depression and anxiety effects on pregnancy and neonatal outcome. Infant Behav Dev, 2010; 33:23–29.
11.
ChungTK, LauTK, YipAS, ChiuHF, LeeDT. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med, 2001; 63:830–834.
12.
SoderquistJ, WijmaB, ThorbertG, WijmaK. Risk factors in pregnancy for post-traumatic stress and depression after childbirth. Br J Obstet Gynaecol, 2009; 116:672–680.
13.
DeaveT, HeronJ, EvansJ, EmondA. The impact of maternal depression in pregnancy on early child development. Br J Obstet Gynaecol, 2008; 115:1043–1051.
FormanDR, O'HaraMW, StuartS, GormanLL, LarsenKE, CoyKC. Effective treatment for postpartum depression is not sufficient to improve the developing mother-child relationship. Dev Psychopathol, 2007; 19:585–602.
16.
HollinsK. Consequences of antenatal mental health problems for child health and development. Curr Opin Obstet Gynecol, 2007; 19:568–572.
17.
MoehlerE, BrunnerR, WiebelA, ReckC, ReschF. Maternal depressive symptoms in the postnatal period are associated with long-term impairment of mother-child bonding. Arch Womens Ment Health, 2006; 9:273–278.
18.
GraceSL, EvindarA, StewartDE. The effect of postpartum depression on child cognitive development and behavior: A review and critical analysis of the literature. Arch Womens Ment Health, 2003; 6:263–274.
19.
SchutterDJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: A meta-analysis. Psychol Med, 2009; 39:65–75.
20.
LamRW, ChanP, Wilkins-HoM, YathamLN. Repetitive transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis. Can J Psychiatry, 2008; 53:621–631.
21.
O'ReardonJP, SolvasonHB, JanicakPGet al.Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial. Biol Psychiatry, 2007; 62:1208–1216.
22.
GeorgeMS, WassermannEM, WilliamsWAet al.Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport, 1995; 6:1853–1856.
23.
PadbergF, GeorgeMS. Repetitive transcranial magnetic stimulation of the prefrontal cortex in depression. Exp Neurol, 2009; 219:2–13.
24.
DaskalakisZJ, LevinsonAJ, FitzgeraldPB. Repetitive transcranial magnetic stimulation for major depressive disorder: A review. Can J Psychiatry, 2008; 53:555–566.
25.
NahasZ, BohningDE, MolloyMA, OustzJA, RischSC, GeorgeMS. Safety and feasibility of repetitive transcranial magnetic stimulation in the treatment of anxious depression in pregnancy: A case report. J Clin Psychiatry, 1999; 60:50–52.
26.
KlirovaM, NovakT, KopecekM, MohrP, StrunzovaV. Repetitive transcranial magnetic stimulation (rTMS) in major depressive episode during pregnancy. Neuro Endocrinol Lett, 2008; 29:69–70.
27.
ZhangD, HuZ. RTMS may be a good choice for pregnant women with depression. Arch Womens Ment Health, 2009; 12:189–190.
28.
GuyW. Clinical Global Impression Scale. Rockville, MD: U.S. Department of Health, Education, and Welfare, 1976.
29.
HamiltonM. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol, 1967; 6:278–296.
30.
FleischmannA, SternheimA, EtgenAM, LiC, GrisaruN, BelmakerRH. Transcranial magnetic stimulation downregulates beta-adrenoreceptors in rat cortex. J Neural Transm, 1996; 103:1361–1366.
FitzgeraldPB, BrownTL, MarstonNA, DaskalakisZJ, De CastellaA, KulkarniJ. Transcranial magnetic stimulation in the treatment of depression: A double-blind, placebo-controlled trial. Arch Gen Psychiatry, 2003; 60:1002–1008.
33.
PridmoreS, Fernandes FilhoJA, NahasZ, LiberatosC, GeorgeMS. Motor threshold in transcranial magnetic stimulation: A comparison of a neurophysiological method and a visualization of movement method. J ECT, 1998; 14:25–27.
34.
BeckAT, WardCH, MendelsonM, MockJ, ErbaughJ. An inventory for measuring depression. Arch Gen Psychiatry, 1961; 4:561–571.
35.
BeckAT, EpsteinN, BrownG, SteerRA. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol, 1988; 56:893–897.
36.
FitzgeraldPB, SritharanA, DaskalakisZJ, de CastellaAR, KulkarniJ, EganG. A functional magnetic resonance imaging study of the effects of low frequency right prefrontal transcranial magnetic stimulation in depression. J Clin Psychopharmacol, 2007; 27:488–492.
37.
SternWM, TormosJM, PressDZ, PearlmanC, Pascual-LeoneA. Antidepressant effects of high and low frequency repetitive transcranial magnetic stimulation to the dorsolateral prefrontal cortex: A double-blind, randomized, placebo-controlled trial. J Neuropsychiatry Clin Neurosci, 2007; 19:179–186.
38.
JanuelD, DumortierG, VerdonCMet al.A double-blind sham controlled study of right prefrontal repetitive transcranial magnetic stimulation (rTMS): Therapeutic and cognitive effect in medication free unipolar depression during 4 weeks. Prog Neuropsychopharmacol Biol Psychiatry, 2006; 30:126–130.
39.
KleinE, KreininI, ChistyakovAet al.Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: A double-blind controlled study. Arch Gen Psychiatry, 1999; 56:315–320.
40.
LevinsonAJ, FitzgeraldPB, FavalliG, BlumbergerDM, DaigleM, DaskalakisZJ. Evidence of cortical inhibitory deficits in major depressive disorder. Biol Psychiatry, 2010; 67:458–464.
41.
McEwenBS. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci, 1991; 12:141–147.
42.
KaskK, BackstromT, LundgrenP, Sundstrom PoromaaI. Allopregnanolone has no effect on startle response and prepulse inhibition of startle response in patients with premenstrual dysphoric disorder or healthy controls. Pharmacol Biochem Behav, 2009; 92:608–613.
43.
LuisiS, PetragliaF, BenedettoCet al.Serum allopregnanolone levels in pregnant women: Changes during pregnancy, at delivery, and in hypertensive patients. J Clin Endocrinol Metab, 2000; 85:2429–2433.
44.
MauriceT, PhanVL, UraniA, KameiH, NodaY, NabeshimaT. Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: Pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol, 1999; 81:125–155.
45.
BaulieuEE. Neurosteroids: A novel function of the brain. Psychoneuroendocrinology, 1998; 23:963–987.
MaguireJ, FerandoI, SimonsenC, ModyI. Excitability changes related to GABAA receptor plasticity during pregnancy. J Neurosci, 2009; 29:9592–9601.
48.
SmithMJ, AdamsLF, SchmidtPJ, RubinowDR, WassermannEM. Abnormal luteal phase excitability of the motor cortex in women with premenstrual syndrome. Biol Psychiatry, 2003; 54:757–762.
49.
JanicakPG, O'ReardonJP, SampsonSMet al.Transcranial magnetic stimulation in the treatment of major depressive disorder: A comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry, 2008; 69:222–232.
50.
GoodmanJH. Women's attitudes, preferences, and perceived barriers to treatment for perinatal depression. Birth, 2009; 36:60–69.
51.
SleathB, WestS, TudorG, PerreiraK, KingV, MorrisseyJ. Ethnicity and depression treatment preferences of pregnant women. J Psychosom Obstet Gynaecol, 2005; 26:135–140.
52.
PedersenLH, HenriksenTB, VestergaardM, OlsenJ, BechBH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: Population based cohort study. BMJ, 2009; 339:b3569.
53.
BoucherN, BairamA, Beaulac-BaillargeonL. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol, 2008; 28:334–339.
54.
ChambersCD, Hernandez-DiazS, Van MarterLJet al.Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med, 2006; 354:579–587.
55.
KallenB, OlaussonPO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf, 2008; 17:801–806.
56.
DimidjianS, GoodmanS. Nonpharmacologic intervention and prevention strategies for depression during pregnancy and the postpartum. Clin Obstet Gynecol, 2009; 52:498–515.
57.
GroteNK, SwartzHA, GeibelSL, ZuckoffA, HouckPR, FrankE. A randomized controlled trial of culturally relevant, brief interpersonal psychotherapy for perinatal depression. Psychiatr Serv, 2009; 60:313–321.
58.
AndersonEL, RetiIM. ECT in pregnancy: A review of the literature from 1941 to 2007. Psychosom Med, 2009; 71:235–242.
